Abstract #0074
13 C MRS of hyperpolarized [1- 13 C] pyruvate can differentiate between SAHA resistant and sensitive glioblastoma cells
Pia Eriksson 1 , Myriam M Chaumeil 1 , Joydeep Mukherjee 2,3 , Russell O Pieper 2,3 , and Sabrina M Ronen 1,3
1
Radiology & Biomedical Imaging, University
of California San Francisco, San Francisco, CA, United
States,
2
Neurological
Surgery, University of California San Francisco, San
Francisco, CA, United States,
3
Brain
Tumor Research Center, University of California San
Francisco, CA, United States
Several currently available drugs with clinical
relevance to GBM affect pyruvate metabolism. In this
study, we show that
13
C
MRS of hyperpolarized [1-
13
C] pyruvate can
also be used to evaluate response to the previously
unexplored drug SAHA in glioblastoma cells. In GBM14
SAHA-sensitive cells, a drop in hyperpolarized [1-
13
C]
pyruvate to [1-
13
C] lactate conversion was
observed after SAHA treatment, while it remained
unchanged in SAHA-resistant cells. Furthermore,
hyperpolarized [1-
13
C] lactate levels were
significantly different between sensitive and resistant
cells both pre- and post-treatment, indicating that this
metabolic imaging technique might also have prognostic
value.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
